MX2017011375A - Método para tratar un tumor cerebral. - Google Patents
Método para tratar un tumor cerebral.Info
- Publication number
- MX2017011375A MX2017011375A MX2017011375A MX2017011375A MX2017011375A MX 2017011375 A MX2017011375 A MX 2017011375A MX 2017011375 A MX2017011375 A MX 2017011375A MX 2017011375 A MX2017011375 A MX 2017011375A MX 2017011375 A MX2017011375 A MX 2017011375A
- Authority
- MX
- Mexico
- Prior art keywords
- treating
- brain tumor
- administering plinabulin
- treatment
- disclosed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Se describen en la presente métodos para tratar un tumor cerebral administrando plinabulina. Algunas modalidades se refieren al tratamiento de glioblastoma multiforme mediante la administración de plinabulina.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562129623P | 2015-03-06 | 2015-03-06 | |
US201562249807P | 2015-11-02 | 2015-11-02 | |
PCT/US2016/020396 WO2016144636A1 (en) | 2015-03-06 | 2016-03-02 | Method of treating a brain tumor |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017011375A true MX2017011375A (es) | 2018-01-23 |
Family
ID=56880412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017011375A MX2017011375A (es) | 2015-03-06 | 2016-03-02 | Método para tratar un tumor cerebral. |
Country Status (17)
Country | Link |
---|---|
US (2) | US10076518B2 (es) |
EP (1) | EP3265091A4 (es) |
JP (2) | JP6904570B2 (es) |
KR (1) | KR102623404B1 (es) |
CN (1) | CN107530340B (es) |
AU (2) | AU2016229295B2 (es) |
BR (1) | BR112017018964A2 (es) |
CA (1) | CA2978679A1 (es) |
CL (1) | CL2017002242A1 (es) |
HK (2) | HK1250007A1 (es) |
IL (1) | IL254262A0 (es) |
MX (1) | MX2017011375A (es) |
MY (1) | MY194341A (es) |
RU (1) | RU2728796C2 (es) |
SG (1) | SG11201707128TA (es) |
WO (1) | WO2016144636A1 (es) |
ZA (1) | ZA201706035B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016229294B2 (en) | 2015-03-06 | 2021-11-04 | Beyondspring Pharmaceuticals, Inc. | Method of treating cancer associated with a RAS mutation |
BR112017018964A2 (pt) | 2015-03-06 | 2018-05-22 | Beyondspring Pharmaceuticals Inc | uso de plinabulin e métodos para tratar tumor cerebral |
DK3334726T3 (da) | 2015-07-13 | 2022-05-16 | Beyondspring Pharmaceuticals Inc | Plinabulinsammensætninger |
CA3013467A1 (en) | 2016-02-08 | 2017-08-17 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
EP3463337A4 (en) | 2016-06-06 | 2020-02-12 | Beyondspring Pharmaceuticals, Inc. | COMPOSITION AND METHOD FOR REDUCING NEUTROPENIA |
WO2018129381A1 (en) | 2017-01-06 | 2018-07-12 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
BR112019015974A2 (pt) | 2017-02-01 | 2020-03-31 | Beyondspring Pharmaceuticals, Inc. | Método para reduzir neutropenia |
US11786523B2 (en) | 2018-01-24 | 2023-10-17 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing thrombocytopenia |
EP3823674A4 (en) | 2018-07-18 | 2022-12-28 | Manzanita Pharmaceuticals, Inc. | CONJUGATES FOR DELIVERING AN ANTI-CANCER AGENT TO NERVE CELLS, METHODS OF USE AND METHODS OF PRODUCTION THEREOF |
WO2021150109A1 (en) * | 2020-01-22 | 2021-07-29 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Abt-751 and ionizing radiation |
MX2022012711A (es) * | 2020-04-10 | 2023-01-16 | Lantern Pharma Inc | Hidroxiureametil-acilfulveno para tratar el cáncer de cerebro o el cáncer del snc. |
WO2022150851A2 (en) * | 2021-01-08 | 2022-07-14 | Lantern Pharma Inc. | Treatment of brain metastases and cns metastases using illudins or hydroxylureamethyl acylfulvene |
WO2022216908A1 (en) * | 2021-04-09 | 2022-10-13 | Beyondspring Pharmaceuticals, Inc. | Therapeutic compositions and methods for treating tumors |
CN117860672A (zh) * | 2022-10-11 | 2024-04-12 | 大连万春布林医药有限公司 | 一种普那布林胶束组合物及其制备方法 |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS509164A (es) | 1973-05-11 | 1975-01-30 | ||
AU576322B2 (en) | 1983-07-22 | 1988-08-25 | Ici Australia Limited | Alpha-substituted-alpha-cyanomethyl alcohols |
US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
JPS6411523A (en) | 1987-07-06 | 1989-01-17 | Kawashima Tekko Kk | Dish feeder in tableware washing machine |
JPH059164A (ja) | 1991-07-02 | 1993-01-19 | Sumitomo Chem Co Ltd | 光学活性マンデロニトリル誘導体の製造方法 |
GB9217331D0 (en) | 1992-08-14 | 1992-09-30 | Xenova Ltd | Pharmaceutical compounds |
PT835657E (pt) | 1992-11-27 | 2004-11-30 | Mayne Pharma Usa Inc | Composicao injectavel estavel de paclitaxel |
JPH0725858A (ja) | 1993-07-13 | 1995-01-27 | Otsuka Pharmaceut Co Ltd | ピペラジン誘導体 |
GB9402809D0 (en) | 1994-02-14 | 1994-04-06 | Xenova Ltd | Pharmaceutical compounds |
GB9402807D0 (en) | 1994-02-14 | 1994-04-06 | Xenova Ltd | Pharmaceutical compounds |
GB9426224D0 (en) | 1994-12-23 | 1995-02-22 | Xenova Ltd | Pharmaceutical compounds |
US5891877A (en) | 1995-02-14 | 1999-04-06 | Xenova Limited | Pharmaceutical compounds |
US5874443A (en) | 1995-10-19 | 1999-02-23 | Trega Biosciences, Inc. | Isoquinoline derivatives and isoquinoline combinatorial libraries |
US5886210A (en) | 1996-08-22 | 1999-03-23 | Rohm And Haas Company | Method for preparing aromatic compounds |
JP3131574B2 (ja) | 1996-09-04 | 2001-02-05 | 新日本製鐵株式会社 | 新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤 |
US5939098A (en) * | 1996-09-19 | 1999-08-17 | Schering Corporation | Cancer treatment with temozolomide |
US5922683A (en) | 1997-05-29 | 1999-07-13 | Abbott Laboratories | Multicyclic erythromycin derivatives |
ES2352739T3 (es) | 1997-11-21 | 2011-02-22 | Purdue Neuroscience Company | 2-aminoacetamidas sustituidas y el uso de las mismas. |
WO1999038844A1 (en) | 1998-01-29 | 1999-08-05 | Aventis Pharmaceuticals Products Inc. | Method for preparing an n-[(aliphatic or aromatic)carbonyl]-2-aminoacetamide compound and a cyclyzed compound |
US7141603B2 (en) | 1999-02-19 | 2006-11-28 | The Regents Of The University California | Antitumor agents |
US6069146A (en) | 1998-03-25 | 2000-05-30 | The Regents Of The University Of California | Halimide, a cytotoxic marine natural product, and derivatives thereof |
IL137974A0 (en) | 1998-03-26 | 2001-10-31 | Shionogi & Co | Indole derivatives having antiviral activity |
US6509331B1 (en) | 1998-06-22 | 2003-01-21 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
FR2784988B1 (fr) | 1998-10-23 | 2002-09-20 | Adir | Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US6358957B1 (en) | 1998-11-12 | 2002-03-19 | Nereus Pharmaceuticals, Inc. | Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds |
US7026322B2 (en) | 1998-11-12 | 2006-04-11 | Nereus Pharmaceuticals, Inc. | Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds |
HU228477B1 (en) | 1999-08-23 | 2013-03-28 | Dana Farber Cancer Inst Inc | Pd-1, a receptor for b7-4, and uses therefor |
PL362804A1 (en) | 1999-08-23 | 2004-11-02 | Dana-Farber Cancer Institute | Novel b7-4 molecules and uses therefor |
CA2392477A1 (en) | 1999-11-30 | 2001-06-07 | Mayo Foundation For Medical Education And Research | B7-h1, a novel immunoregulatory molecule |
KR100831400B1 (ko) | 2000-01-18 | 2008-05-21 | 니리어스 파마슈티컬즈, 인크. | 세포분열 저해제 및 그의 제조방법 |
HUP0302358A3 (en) | 2000-05-09 | 2007-09-28 | Adpharma | Piperazinedione compounds and use of them for producing pharmaceutical compositions |
JP2004518731A (ja) | 2000-12-28 | 2004-06-24 | ニューロクライン バイオサイエンシーズ, インコーポレイテッド | 三環式crfレセプターアンタゴニスト |
US7012100B1 (en) | 2002-06-04 | 2006-03-14 | Avolix Pharmaceuticals, Inc. | Cell migration inhibiting compositions and methods and compositions for treating cancer |
US7935704B2 (en) | 2003-08-01 | 2011-05-03 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
IL166628A0 (en) | 2002-08-02 | 2006-01-15 | Nereus Pharmaceuticals Inc | Dehydrophenyl lahistins and analogs thereof and the synthesis of dehydrophenyllahistins and analogs thereof |
US7919497B2 (en) * | 2002-08-02 | 2011-04-05 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
NZ548659A (en) | 2004-02-04 | 2011-01-28 | Nereus Pharmaceuticals Inc | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
DE202004018940U1 (de) | 2004-12-07 | 2006-04-13 | Asf Verwaltungs Gmbh | Druckverschluß, Druckverschlußband und wiederverschließbarer Beutel |
CA2607147C (en) | 2005-05-09 | 2018-07-17 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
JP5252635B2 (ja) | 2005-07-01 | 2013-07-31 | メダレックス インコーポレーティッド | プログラム死リガンド1(pd−l1)に対するヒトモノクローナル抗体 |
ES2425396T3 (es) * | 2006-01-18 | 2013-10-15 | Merck Patent Gmbh | Terapia específica usando ligandos de integrinas para el tratamiento del cáncer |
US8129527B2 (en) | 2006-11-03 | 2012-03-06 | Nereus Pharmacuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
WO2009089260A2 (en) | 2008-01-08 | 2009-07-16 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
LT4209510T (lt) | 2008-12-09 | 2024-03-12 | F. Hoffmann-La Roche Ag | Anti-pd-l1 antikūnai ir jų panaudojimas t ląstelių funkcijos pagerinimui |
WO2010114922A1 (en) * | 2009-03-31 | 2010-10-07 | Agios Pharmaceuticals, Inc. | Methods of treating cancer having an aberrant egfr or kras genotype |
GB0907551D0 (en) | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
TWI483938B (zh) * | 2009-08-10 | 2015-05-11 | Univ Texas | 以內皮素受體抑制劑處理星狀腫瘤細胞 |
PT2504364T (pt) | 2009-11-24 | 2017-11-14 | Medimmune Ltd | Agentes de ligação direcionados contra b7-h1 |
US20130064831A1 (en) | 2010-05-17 | 2013-03-14 | Bristol-Myers Squibb Company | Immunotherapeutic dosing regimens and combinations thereof |
CA2799653A1 (en) * | 2010-06-04 | 2011-12-08 | Bertrand Leblond | Substituted isoquinolines and their use as tubulin polymerization inhibitors |
JP2012033526A (ja) | 2010-07-28 | 2012-02-16 | Fuji Electric Co Ltd | 薄膜太陽電池およびその製造方法 |
WO2012035436A1 (en) | 2010-09-15 | 2012-03-22 | Tokyo University Of Pharmacy And Life Sciences | Plinabulin prodrug analogs and therapeutic uses thereof |
TWI386203B (zh) * | 2011-01-07 | 2013-02-21 | Univ China Medical | 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用 |
CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
AU2013204313C1 (en) * | 2012-06-01 | 2016-04-07 | Bionomics Limited | Combination Therapy |
WO2014160183A1 (en) | 2013-03-13 | 2014-10-02 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Methods for modulating chemotherapeutic cytotoxicity |
JP6526627B2 (ja) * | 2013-04-24 | 2019-06-05 | テル ハショメール メディカル リサーチ インフラストラクチャー アンド サービシズ リミテッド | 組織解析用の磁気共鳴マップ |
MY185650A (en) | 2013-10-11 | 2021-05-27 | Beyondspring Inc | Cancer treatment with combinantion of plinabulin and taxane |
US9850225B2 (en) | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
SG11201706281YA (en) | 2015-02-12 | 2017-09-28 | Beyondspring Pharmaceuticals Inc | Use of plinabulin in combination with immune checkpoint inhibitors |
BR112017018964A2 (pt) | 2015-03-06 | 2018-05-22 | Beyondspring Pharmaceuticals Inc | uso de plinabulin e métodos para tratar tumor cerebral |
AU2016229294B2 (en) | 2015-03-06 | 2021-11-04 | Beyondspring Pharmaceuticals, Inc. | Method of treating cancer associated with a RAS mutation |
DK3334726T3 (da) | 2015-07-13 | 2022-05-16 | Beyondspring Pharmaceuticals Inc | Plinabulinsammensætninger |
CA3013467A1 (en) | 2016-02-08 | 2017-08-17 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
EP3463337A4 (en) | 2016-06-06 | 2020-02-12 | Beyondspring Pharmaceuticals, Inc. | COMPOSITION AND METHOD FOR REDUCING NEUTROPENIA |
WO2018129381A1 (en) | 2017-01-06 | 2018-07-12 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
BR112019015974A2 (pt) | 2017-02-01 | 2020-03-31 | Beyondspring Pharmaceuticals, Inc. | Método para reduzir neutropenia |
NZ757213A (en) | 2017-03-13 | 2022-01-28 | Beyondspring Pharmaceuticals Inc | Compositions of plinabulin and use thereof |
-
2016
- 2016-03-02 BR BR112017018964A patent/BR112017018964A2/pt not_active Application Discontinuation
- 2016-03-02 JP JP2017546767A patent/JP6904570B2/ja active Active
- 2016-03-02 MY MYPI2017703256A patent/MY194341A/en unknown
- 2016-03-02 AU AU2016229295A patent/AU2016229295B2/en active Active
- 2016-03-02 CN CN201680020652.9A patent/CN107530340B/zh active Active
- 2016-03-02 RU RU2017131448A patent/RU2728796C2/ru active
- 2016-03-02 MX MX2017011375A patent/MX2017011375A/es unknown
- 2016-03-02 US US15/555,956 patent/US10076518B2/en active Active
- 2016-03-02 KR KR1020177026283A patent/KR102623404B1/ko active IP Right Grant
- 2016-03-02 SG SG11201707128TA patent/SG11201707128TA/en unknown
- 2016-03-02 EP EP16762150.7A patent/EP3265091A4/en active Pending
- 2016-03-02 WO PCT/US2016/020396 patent/WO2016144636A1/en active Application Filing
- 2016-03-02 CA CA2978679A patent/CA2978679A1/en active Pending
-
2017
- 2017-08-31 IL IL254262A patent/IL254262A0/en unknown
- 2017-09-04 CL CL2017002242A patent/CL2017002242A1/es unknown
- 2017-09-05 ZA ZA2017/06035A patent/ZA201706035B/en unknown
-
2018
- 2018-07-03 HK HK18108504.2A patent/HK1250007A1/zh unknown
- 2018-07-10 HK HK18108933.3A patent/HK1249051A1/zh unknown
- 2018-09-05 US US16/122,482 patent/US10357491B2/en active Active
-
2021
- 2021-02-22 JP JP2021026411A patent/JP7264331B2/ja active Active
- 2021-10-19 AU AU2021254549A patent/AU2021254549A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2016229295A1 (en) | 2017-09-28 |
US10357491B2 (en) | 2019-07-23 |
ZA201706035B (en) | 2019-12-18 |
RU2017131448A3 (es) | 2019-08-20 |
JP7264331B2 (ja) | 2023-04-25 |
KR20170123642A (ko) | 2017-11-08 |
CA2978679A1 (en) | 2016-09-15 |
US20180042921A1 (en) | 2018-02-15 |
SG11201707128TA (en) | 2017-09-28 |
US20190000841A1 (en) | 2019-01-03 |
US10076518B2 (en) | 2018-09-18 |
CN107530340B (zh) | 2021-06-08 |
IL254262A0 (en) | 2017-10-31 |
EP3265091A4 (en) | 2018-08-01 |
JP2018507245A (ja) | 2018-03-15 |
AU2021254549A1 (en) | 2021-11-18 |
CL2017002242A1 (es) | 2018-04-02 |
HK1249051A1 (zh) | 2018-10-26 |
WO2016144636A1 (en) | 2016-09-15 |
JP2021091695A (ja) | 2021-06-17 |
AU2016229295B2 (en) | 2021-11-04 |
EP3265091A1 (en) | 2018-01-10 |
RU2728796C2 (ru) | 2020-07-31 |
KR102623404B1 (ko) | 2024-01-11 |
RU2017131448A (ru) | 2019-04-08 |
BR112017018964A2 (pt) | 2018-05-22 |
HK1250007A1 (zh) | 2018-11-23 |
MY194341A (en) | 2022-11-29 |
CN107530340A (zh) | 2018-01-02 |
JP6904570B2 (ja) | 2021-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY194341A (en) | Method of treating a brain tumor | |
MX2021004881A (es) | Combinacion de palbociclib y rad1901 para usarse en el tratamiento de cancer de mama en un sujeto con cancer positivo a receptor de estrogeno. | |
MY190034A (en) | Method of treating cancer associated with a ras mutation | |
PH12015502075A1 (en) | Treatment of cataplexy | |
MX2017010150A (es) | Bacterias probioticas recombinantes. | |
EA201891340A1 (ru) | Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек | |
PH12019500135A1 (en) | Methods of treating prostate cancer | |
NZ722600A (en) | Methods of treating mild brain injury | |
NZ738672A (en) | Therapeutic compounds and compositions for treating social disorders and substance use disorders | |
SG10201804034QA (en) | Methods for treating hypotension | |
MY195000A (en) | Method for the treatment of neurological disease | |
ZA201803483B (en) | Method of treating disease by auricular anesthesia of cranial nerves | |
MX2020009966A (es) | Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina. | |
HK1253299A1 (zh) | 一種通過基因治療治療眼疾病的改進方法 | |
TW201613639A (en) | Methods for treating cardiovascular diseases | |
MX2019004804A (es) | Tratamiento para el prurigo nodula. | |
JO3541B1 (ar) | علاجات طبية قائمة على اناموريلين | |
MX2018011379A (es) | Tratamiento del prurito uremico. | |
MX2023003924A (es) | Metodos de administracion de tratamiento antifibrotico. | |
MX2016002307A (es) | Tratamiento para el cancer. | |
MX2017013669A (es) | Composiciones para el tramiento del cancer. | |
NZ750581A (en) | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy | |
EA201990411A1 (ru) | Способы лечения рака предстательной железы | |
UA107743C2 (ru) | Способ лечения аденокарциномы |